WikiJournalClub:Usable articles: Difference between revisions

Jump to navigation Jump to search

WikiJournalClub:Usable articles (view source)

Revision as of 18:12, 31 March 2016

3,319 bytes removed ,  31 March 2016
no edit summary
No edit summary
No edit summary
Line 1: Line 1:
The following are articles in [[:Category:Usable articles]].
The following are articles in [[:Category:Usable articles]].
==Allergy and Immunology==
'''Asthma'''
* [[EXTRA]] (2011): Omalizumab in severe allergic asthma


==Cardiology==
==Cardiology==
Line 10: Line 6:
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[CAST I]] (1991): Antiarrhythmics post-MI
* [[CAST I]] (1991): Antiarrhythmics post-MI
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
* [[COMMIT]] (2005): Metoprolol in acute MI
* [[COMMIT]] (2005): Metoprolol in acute MI
* [[CURE]] (2001): Clopidogrel in UA/NSTEMI
* [[CURE]] (2001): Clopidogrel in UA/NSTEMI
Line 60: Line 55:


'''Cardiovascular Disease'''
'''Cardiovascular Disease'''
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Line 75: Line 69:
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD
* [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[CARP]] (2004): Preop coronary revascularization if stable CAD
* [[CARP]] (2004): Preop coronary revascularization if stable CAD
* [[COGENT]] (2010): PPI plus clopidogrel in CAD
* [[COGENT]] (2010): PPI plus clopidogrel in CAD
Line 86: Line 79:
* [[HPS2-THRIVE]] (2014): Niacin in atherosclerotic disease
* [[HPS2-THRIVE]] (2014): Niacin in atherosclerotic disease
* [[JUPITER]] (2008): Rosuvastatin for primary CV prevention
* [[JUPITER]] (2008): Rosuvastatin for primary CV prevention
* [[LoDoCo]] (2013): Colchicine for stable CAD
* [[MIRACL]] (2001): Atorvastatin in UA/NSTEMI
* [[MIRACL]] (2001): Atorvastatin in UA/NSTEMI
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD
Line 153: Line 145:
* [[ALLHAT]] (2002): Chlorthalidone in HTN
* [[ALLHAT]] (2002): Chlorthalidone in HTN
* [[DASH]] (1997): DASH diet in HTN
* [[DASH]] (1997): DASH diet in HTN
* [[HYVET]] (2008): Elderly HTN treatment
* [[SPRINT]] (2015): BP targets in high-risk patients
* [[SPRINT]] (2015): BP targets in high-risk patients


Line 165: Line 156:
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS
* [[CAST I]] (1991): Antiarrhythmics post-MI
* [[CAST I]] (1991): Antiarrhythmics post-MI
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
* [[COMMIT]] (2005): Metoprolol in acute MI
* [[COMMIT]] (2005): Metoprolol in acute MI
* [[DAPT]] (2014): Aspirin/clopidogrel duration after PCI
* [[DAPT]] (2014): Aspirin/clopidogrel duration after PCI
Line 208: Line 198:
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[BRIDGE]] (2015): LMWH bridging for surgery in AF
* [[BRIDGE]] (2015): LMWH bridging for surgery in AF
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
Line 228: Line 216:
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
Line 272: Line 259:
* [[SEDCOM]] (2009): Dexmedetomidine vs. midazolam for sedation
* [[SEDCOM]] (2009): Dexmedetomidine vs. midazolam for sedation
* [[Yang-Tobin Study]] (1991): RSBI for predicting weaning
* [[Yang-Tobin Study]] (1991): RSBI for predicting weaning
'''Gastrointestinal Hemorrhage'''
* [[GI bleeding in ICU patients]] (1994): Risk factors for GI bleeds in ICU patients


'''Heart Failure'''
'''Heart Failure'''
Line 294: Line 278:


'''Sepsis'''
'''Sepsis'''
* [[ALBIOS]] (2014): Daily albumin in severe sepsis
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[ARISE]] (2014): EGDT vs. usual care in sepsis
* [[ARISE]] (2014): EGDT vs. usual care in sepsis
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
* [[ProCESS]] (2014): EGDT in septic shock
* [[ProCESS]] (2014): EGDT in septic shock
* [[PROWESS]] (2001): Activated protein C in severe sepsis
* [[PROWESS]] (2001): Activated protein C in severe sepsis
Line 309: Line 291:
'''Shock'''
'''Shock'''
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
* [[CRISTAL]] (2013): Colloids vs. crystalloids in shock
* [[CRISTAL]] (2013): Colloids vs. crystalloids in shock
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
Line 379: Line 360:


'''Diabetes Mellitus'''
'''Diabetes Mellitus'''
* [[ACCORD]] (2008): Intensive glycemic therapy in T2DM
* [[ACCORD BP]] (2010): Intensive BP control in T2DM
* [[ACCORD BP]] (2010): Intensive BP control in T2DM
* [[ADVANCE]] (2008): Intensive glycemic therapy in T2DM
* [[ADVANCE]] (2008): Intensive glycemic therapy in T2DM
Line 387: Line 367:
* [[EDIC]] (2005): Intensive glycemic therapy in T1DM
* [[EDIC]] (2005): Intensive glycemic therapy in T1DM
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Line 400: Line 379:
'''Diabetic Nephropathy'''
'''Diabetic Nephropathy'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy


Line 408: Line 386:
'''Obesity'''
'''Obesity'''
* [[STAMPEDE]] (2012): Gastric bypass vs. medical therapy for T2DM
* [[STAMPEDE]] (2012): Gastric bypass vs. medical therapy for T2DM
'''Sepsis'''
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
'''Shock'''
* [[CORTICUS]] (2008): Hydrocortisone in septic shock


'''Stress Hyperglycemia'''
'''Stress Hyperglycemia'''
Line 427: Line 399:
* [[Prednisolone in Severe Alcoholic Hepatitis]] (1992): Prednisolone vs. placebo in alcoholic hepatitis
* [[Prednisolone in Severe Alcoholic Hepatitis]] (1992): Prednisolone vs. placebo in alcoholic hepatitis
* [[STOPAH]] (2015): Prednisolone vs. pentoxifylline in alcoholic hepatitis
* [[STOPAH]] (2015): Prednisolone vs. pentoxifylline in alcoholic hepatitis
'''Cirrhosis'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed


'''Clostridium difficile'''
'''Clostridium difficile'''
Line 438: Line 407:
'''Crohn Disease'''
'''Crohn Disease'''
* [[SONIC]] (2010): Infliximab ± azathioprine induction in Crohn disease
* [[SONIC]] (2010): Infliximab ± azathioprine induction in Crohn disease
'''Gastrointestinal Hemorrhage'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
* [[GI bleeding in ICU patients]] (1994): Risk factors for GI bleeds in ICU patients
* [[Omeprazole in Peptic Ulcer Bleeding]] (2000): IV PPI for GI bleeds
'''Hepatic Encephalopathy'''
* [[Rifaximin and Lactulose for HE]] (2013): Rifaximin/lactulose vs. lactulose for acute HE


'''Hepatitis C'''
'''Hepatitis C'''
Line 452: Line 413:
'''Inflammatory Bowel Disease'''
'''Inflammatory Bowel Disease'''
* [[SONIC]] (2010): Infliximab ± azathioprine induction in Crohn disease
* [[SONIC]] (2010): Infliximab ± azathioprine induction in Crohn disease
'''Pancreatitis'''
* [[PANTER]] (2010): Step-up approach to pancreatitis
==Geriatrics==
'''Hypertension'''
* [[HYVET]] (2008): Elderly HTN treatment


==Gynecology==
==Gynecology==
Line 556: Line 510:


==Infectious Disease==
==Infectious Disease==
'''Cirrhosis'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
'''Clostridium difficile'''
'''Clostridium difficile'''
* [[Fidaxomicin in C. difficile Diarrhea]] (2011): Fidaxomicin in C. difficile
* [[Fidaxomicin in C. difficile Diarrhea]] (2011): Fidaxomicin in C. difficile
Line 567: Line 518:
* [[3SITES]] (2015): Central line complications by insertion site
* [[3SITES]] (2015): Central line complications by insertion site
* [[PRORATA]] (2010): Procalcitonin-guided antibiotics
* [[PRORATA]] (2010): Procalcitonin-guided antibiotics
'''Gastrointestinal Hemorrhage'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed


'''HIV'''
'''HIV'''
Line 577: Line 525:
* [[INSIGHT START]] (2015): Early vs. delayed ART in HIV
* [[INSIGHT START]] (2015): Early vs. delayed ART in HIV
* [[IPrEx]] (2010): ART in primary HIV prevention
* [[IPrEx]] (2010): ART in primary HIV prevention
* [[NA-ACCORD]] (2009): Early vs. delayed ART in HIV


'''Hepatitis C'''
'''Hepatitis C'''
Line 625: Line 572:
'''Diabetes Mellitus'''
'''Diabetes Mellitus'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[RENAAL]] (2001): ARBs in diabetic nephropathy
* [[RENAAL]] (2001): ARBs in diabetic nephropathy
Line 633: Line 579:
'''Diabetic Nephropathy'''
'''Diabetic Nephropathy'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy


Line 640: Line 585:
* [[ASTRAL]] (2009): Revascularization in RAS
* [[ASTRAL]] (2009): Revascularization in RAS
* [[DASH]] (1997): DASH diet in HTN
* [[DASH]] (1997): DASH diet in HTN
* [[HYVET]] (2008): Elderly HTN treatment


'''Kidney Transplant'''
'''Kidney Transplant'''
Line 677: Line 621:


'''Coronary Artery Disease'''
'''Coronary Artery Disease'''
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[HOPE]] (2000): Ramipril in patients with high CV risk
* [[HOPE]] (2000): Ramipril in patients with high CV risk
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD
Line 696: Line 639:
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[CHANCE]] (2013): ASA/clopidogrel vs. ASA in TIA/stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
* [[ECASS III]] (2008): Alteplase 3-4.5h after stroke
* [[ECST]] (1998): CEA in symptomatic carotid stenosis
* [[ECST]] (1998): CEA in symptomatic carotid stenosis
* [[ESPRIT]] (2006): ASA+dipyridamole in secondary stroke prevention
* [[ESPRIT]] (2006): ASA+dipyridamole in secondary stroke prevention
* [[FLAME]] (2011): SSRI after CVA for motor recovery
* [[HOPE]] (2000): Ramipril in patients with high CV risk
* [[HOPE]] (2000): Ramipril in patients with high CV risk
* [[IST]] (1997): Aspirin in acute ischemic stroke
* [[MATCH]] (2004): ASA/clopidogrel vs. clopidogrel in stroke
* [[MR CLEAN]] (2015): IA therapy for proximal large artery strokes
* [[MR CLEAN]] (2015): IA therapy for proximal large artery strokes
* [[MR RESCUE]] (2013): Thrombectomy vs. standard care in stroke
* [[MR RESCUE]] (2013): Thrombectomy vs. standard care in stroke
Line 718: Line 655:
* [[ROCKET AF]] (2011): Rivaroxaban vs. warfarin in AF
* [[ROCKET AF]] (2011): Rivaroxaban vs. warfarin in AF
* [[SPARCL]] (2006): Atorvastatin after stroke
* [[SPARCL]] (2006): Atorvastatin after stroke
* [[SPS3-BP]] (2013): SBP <130 vs. SBP 130-150 after lacunar strokes


'''Transient Ischemic Attack'''
'''Transient Ischemic Attack'''
Line 725: Line 661:
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[AVERROES]] (2011): Apixaban vs. ASA in AF
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease
* [[CHANCE]] (2013): ASA/clopidogrel vs. ASA in TIA/stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis
Line 811: Line 745:


==Pediatrics==
==Pediatrics==
'''Asthma'''
* [[EXTRA]] (2011): Omalizumab in severe allergic asthma
'''Shock'''
'''Shock'''
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
Line 881: Line 812:


'''Depression'''
'''Depression'''
* [[Can-SAD]] (2006): Light therapy vs. SSRI for SAD
* [[SADHART]] (2002): Sertraline for depression post-ACS
* [[SADHART]] (2002): Sertraline for depression post-ACS
* [[STAR-D]] (2006): Tiered approach for depression
* [[STAR-D]] (2006): Tiered approach for depression
Line 887: Line 817:
'''Schizophrenia'''
'''Schizophrenia'''
* [[CATIE]] (2005): Antipsychotics in schizophrenia
* [[CATIE]] (2005): Antipsychotics in schizophrenia
'''Seasonal Affective Disorder'''
* [[Can-SAD]] (2006): Light therapy vs. SSRI for SAD


==Pulmonology==
==Pulmonology==
Line 897: Line 824:
'''Asthma'''
'''Asthma'''
* [[BASALT]] (2012): Symptom-based asthma therapy
* [[BASALT]] (2012): Symptom-based asthma therapy
* [[EXTRA]] (2011): Omalizumab in severe allergic asthma
* [[SMART]] (2006): Salmeterol in asthma
* [[SMART]] (2006): Salmeterol in asthma
* [[TALC]] (2010): Tiotropium vs. others in asthma
* [[TALC]] (2010): Tiotropium vs. others in asthma
Line 1,006: Line 932:
* [[METEOR]] (2013): Surgery vs. PT in OA with meniscal tear
* [[METEOR]] (2013): Surgery vs. PT in OA with meniscal tear
* [[Moseley Trial]] (2002): Arthroscopy in knee OA
* [[Moseley Trial]] (2002): Arthroscopy in knee OA
'''Pancreatitis'''
* [[PANTER]] (2010): Step-up approach to pancreatitis


'''Renal Cell Carcinoma'''
'''Renal Cell Carcinoma'''
WJCBot
Bots, editor, reviewer, Administrators
13,941

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/21722"

Navigation menu